London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Descemet membrane perforation: management of deep anterior lameller keratoplasty specific complication

Poster Details

First Author: B.Torun Acar TURKEY

Co Author(s):    K. Bozkurt   S. Acar           

Abstract Details

Purpose:

To report the management of descemet membrane perforation in deep anterior lamellar keratoplasty (DALK).

Setting:

Haydarpasa Numune Education and Research Hospital, Ophthalmology Clinic, Istanbul, Turkey.

Methods:

Medical charts and surgical records of 340 eyes of 262 patients who underwent DALK using Anwar’s big-bubble technique in our cornea clinic were reviewed. Intra-operative microperforations (size, location and steps of the surgery in which DM perforation occurred) and their management were evaluated.Of the 340 attempted DALK surgeries, 325 surgery was accomplished as DALK. Descemet membrane perforation occurred in 58 eyes (macroperforation in 4 eyes and microperforation in 54 eyes). Ten surgery were converted to penetrating keratoplasty (PK) due to descemet membrane perforation during trephination (4 eyes ) and enlargement of the microperforation (6 eyes). In 5 eyes, central microperforation occurred, surgeries were converted to PK. In remaining 43 eyes microperforation did not enlarge and surgeries were accomplished as DALK.

Results:

Management of DM perforation as a complication of DALK surgery has its own particular specifications which entirely differ from conventional PK. Our experience may reveal tips about managing DM to increase possibility of accomplishing DALK after the event of a DM perforation.

Conclusions:

-

Financial Disclosure:

NONE

Back to Poster listing